Immune checkpoint inhibitor-induced myocarditis: focus on the downstream pathogenic components and potential therapeutics
Seminars in Cancer Biology · 2026
DOI: 10.1016/j.semcancer.2025.12.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Cancer Biology, 2026. Verfasst von Yifan Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for …. Hauptthemen laut MEDLINE: Myocarditis, Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 101 Literaturangaben. Gefördert von: Chinese Academy of Medical Sciences, National Natural Science Foundation of China, Shanghai Shenkang Hospital Development Center.
Abstract (Originalsprache)
Advent of immune checkpoint inhibitors (ICIs) has renovated onco-immunotherapy, with around 50 % of cancer patients suitable for the treatment. However, patients treated by ICIs are in jeopardy for immune-related adverse events (irAEs) that attack any organ including the heart. ICIs-induced myocarditis (ICIIM) is an uncommon but possibly fatal irAE. With the increasing use of ICIs and improved diagnosis of this disease, the incidence of ICIIM is growing rapidly. In this review, we briefly overview roles of T cells and their immune checkpoints, and categorize the pathogenic process of ICIIM into three stages (upstream, midstream and downstream), with addressing recent research progress on the pathogenic mechanisms in each stage, particularly focusing on the downstream core pathogenic components and potential therapeutics for this disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai 200032, China; Department of Cardiol…
- Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai Institute of Medical Imaging,…
- Department of Cardiology, Fujian Medical University Union Hospital, Fujian Provincial Center for Cardiovascular Medicine, Fujian Institute of Coronary Artery Disease, Fuzhou 350001, China.
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai 200032, China. Electronic address: j…
Förderung
- Chinese Academy of Medical Sciences
- National Natural Science Foundation of China
- Shanghai Shenkang Hospital Development Center
Zitieren
APA
Chen, Y., Wang, X., Shen, Y., Zhang, H., Yu, C., Cheng, L., & Ge, J. (2026). Immune checkpoint inhibitor-induced myocarditis: focus on the downstream pathogenic components and potential therapeutics. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2025.12.004
Vancouver
Chen Y, Wang X, Shen Y, Zhang H, Yu C, Cheng L, et al. Immune checkpoint inhibitor-induced myocarditis: focus on the downstream pathogenic components and potential therapeutics. Seminars in Cancer Biology. 2026. doi:10.1016/j.semcancer.2025.12.004
BibTeX
@article{Chen2026,
author = {Chen, Yifan and Wang, Xuejun and Shen, Yihui and Zhang, Hui and Yu, Cheng and Cheng, Leilei and Ge, Junbo},
title = {Immune checkpoint inhibitor-induced myocarditis: focus on the downstream pathogenic components and potential therapeutics},
journal = {Seminars in Cancer Biology},
year = {2026},
doi = {10.1016/j.semcancer.2025.12.004}
}
EUVIMED